NCT05655715
Checkpoint Inhibitors and SBRT for MCRPC treatment 2 completed NCT03432780
Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer prevention 2 unknown_status NCT03012321
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects treatment 2 active_not_recruiting NCT02985021
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies treatment 2 terminated NCT03707184
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone diagnostic 2 completed NCT02184533
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer treatment 1 completed NCT02935205
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer treatment 1 / 2 recruiting NCT01023061
Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer treatment 2 completed NCT00330161
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer treatment 2 completed NCT01498978
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 completed NCT02278185
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer supportive_care 2 active_not_recruiting NCT01949337
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer treatment 3 active_not_recruiting NCT00103337
Cilengitide in Treating Patients With Metastatic Prostate Cancer treatment 2 completed NCT01468532
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 1 / 2 completed NCT01555632
Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy treatment Not Available withdrawn NCT01385059
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer treatment 2 completed NCT00936975
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases No drug interventions diagnostic 2 completed NCT04267575
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites No drug interventions treatment Not Available unknown_status NCT01050842
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer treatment 0 completed NCT02058706
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer treatment 2 completed NCT01120236
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer treatment 2 completed NCT02646319
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations treatment 0 completed NCT00879619
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients treatment 1 / 2 terminated NCT00003517
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer treatment 2 withdrawn NCT00003534
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer treatment 2 withdrawn NCT01992016
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine diagnostic Not Available completed NCT02499835
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer treatment 1 / 2 completed NCT01117935
Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer No drug interventions treatment Not Available completed NCT02023463
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer treatment 1 active_not_recruiting NCT02169063
Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer No drug interventions diagnostic Not Available withdrawn NCT00087139
Ixabepilone in Treating Patients With Metastatic Prostate Cancer treatment 2 completed NCT00005039
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) treatment 2 terminated NCT00074022
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors treatment 1 / 2 completed NCT01685125
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 unknown_status NCT00170157
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer treatment 2 completed NCT01703065
Cabozantinib in Men With Castration-Resistant Prostate Cancer treatment 2 terminated NCT01807065
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer treatment 2 completed NCT02228265
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide Not Available Not Available completed NCT01522820
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors treatment 1 completed NCT01543776
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer treatment 2 completed NCT03805594
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer treatment 1 active_not_recruiting NCT00089362
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors treatment 1 completed NCT00118092
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy treatment 2 completed NCT00331344
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy treatment 1 / 2 completed NCT01881867
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 completed NCT00937768
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy treatment 2 terminated NCT00031681
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) treatment 1 completed NCT02598895
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway treatment 2 completed NCT01519414
Tivantinib in Treating Patients With Metastatic Prostate Cancer treatment 2 completed NCT00040755
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy treatment 2 completed NCT02615223
Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer treatment Not Available unknown_status NCT01145508
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 terminated NCT01469338
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel supportive_care 2 terminated NCT03477864
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer treatment 1 withdrawn NCT00058084
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer treatment 2 completed NCT00058253
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors treatment 1 completed NCT00337077
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy treatment 2 completed NCT00030498
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction treatment 1 completed NCT02807805
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer treatment 2 active_not_recruiting NCT02491411
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel treatment Not Available terminated NCT03344211
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer treatment 2 active_not_recruiting NCT01599793
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer diagnostic 2 completed NCT03123978
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer treatment 1 completed NCT00016107
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer treatment 2 completed NCT01913015
Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 1 terminated NCT02516670
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer treatment 2 terminated NCT02881242
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer treatment 2 active_not_recruiting NCT01174199
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer treatment 1 terminated NCT00096499
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel treatment 2 completed NCT02050906
Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy No drug interventions supportive_care Not Available active_not_recruiting NCT02144649
Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery No drug interventions treatment Not Available completed NCT03016741
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer supportive_care 4 unknown_status NCT01682941
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen No drug interventions treatment Not Available completed NCT02206334
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer No drug interventions treatment 1 completed NCT00527124
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy treatment 2 terminated NCT04113096
Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer No drug interventions treatment 0 unknown_status NCT02012296
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer treatment 1 / 2 completed NCT03511196
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer treatment 0 active_not_recruiting NCT01155258
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors treatment 1 completed NCT00956163
Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer No drug interventions diagnostic 0 completed NCT03880422
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors No drug interventions supportive_care Not Available recruiting NCT05025748
Ask Questions (ASQ):Implementation of a Communication Intervention No drug interventions health_services_research Not Available completed NCT05189457
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer treatment 2 active_not_recruiting NCT02489357
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer treatment Not Available completed NCT01267266
Saracatinib in Treating Patients With Prostate Cancer treatment 2 terminated NCT00666666
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer treatment 2 completed NCT02603965
Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery No drug interventions diagnostic 1 completed NCT00004074
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu treatment 1 completed NCT01912820
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery prevention 1 completed NCT03827473
Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer treatment 2 terminated NCT00536991
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer treatment 1 / 2 terminated NCT01270880
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy treatment 2 completed NCT01240629
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 1 / 2 completed NCT00095667
Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer treatment 2 completed NCT01848067
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer treatment 1 / 2 completed NCT00039104
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer treatment 2 completed NCT03112668
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners No drug interventions supportive_care Not Available completed NCT01812668
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer treatment Not Available completed NCT01533246
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer treatment 2 completed NCT00020046
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer treatment 2 completed NCT01731912
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer treatment Not Available completed NCT03596710
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy No drug interventions diagnostic Not Available withdrawn NCT01200810
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer treatment 2 terminated NCT00019695
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer treatment 2 terminated NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy treatment 3 completed NCT00058214
Perifosine in Treating Patients With Recurrent Prostate Cancer treatment 2 terminated NCT02159950
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 completed NCT02048150
Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer No drug interventions diagnostic 1 completed NCT01866423
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer treatment 2 terminated NCT01026623
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer treatment 1 / 2 completed NCT01833208
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T No drug interventions treatment Not Available completed